[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-332782-105":59,"doc-detail-332782-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","survival-rate-comparisons-of-angioembolization-and-neoadjuvant-targeted-therapy-on-unresectable-renal-cell-carcinoma-patients-systematic-review","Survival rate comparisons of angioembolization and neoadjuvant targeted therapy on unresectable renal cell carcinoma patients - systematic review","","Renal cell cancer (RCC) is the dominant kidney cancer in adults and often progresses despite standard surgery, since 20%–40% of localized cases can develop distant metastases and unresectable disease requires palliative management. Angioembolization and neoadjuvant targeted therapy are used for unresectable RCC, but comparative survival evidence is unclear. This systematic review compared survival outcomes between angioembolization and neoadjuvant targeted agents by searching PubMed, Cochrane Library, and ProQuest (2018–2023), excluding duplicates and irrelevant reviews to retain six pertinent studies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/survival-rate-comparisons-of-angioembolization-and-neoadjuvant-targeted-therapy-on-unresectable-renal-cell-carcinoma-patients-systematic-review/332782/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/survival-rate-comparisons-of-angioembolization-and-neoadjuvant-targeted-therapy-on-unresectable-renal-cell-carcinoma-patients-systematic-review/332782.png","ImageObject",300,407,{"name":92,"@type":93},"Quinn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What condition does this systematic review focus on?","Question",{"text":112,"@type":113},"Unresectable renal cell carcinoma (RCC) in patients requiring palliative treatment, where surgery is not suitable due to metastases or large tumor burden.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which interventions are compared for survival outcomes?",{"text":117,"@type":113},"Angioembolization is compared with neoadjuvant targeted therapy agents in terms of overall survival.",{"name":119,"@type":110,"acceptedAnswer":120},"How was the review conducted and what studies were included?",{"text":121,"@type":113},"Databases including PubMed, Cochrane Library, and ProQuest were searched for articles published from 2018 to 2023, with duplicates, reviews, and incomplete articles excluded, resulting in six relevant articles.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},332782,1790240466,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":4},962075114765,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","| Review Article |  |\n| --- | --- |\n|  |  |\n| Survival rate comparisons of angioembolization and neoadjuvant targeted therapy on unresectable renal cell carcinoma patients: A systematic review\u003Cbr>Rifqi Yanda Muhammad, Derri Hafa Nurfajri, Dahril Dahril1, Jufriady Ismy1\u003Cbr>Department of Urology, Hasan Sadikin Academic Medical Center, Faculty of Medicine, Padjadjaran University, Bandung, 1 Department of Surgery, Urology Division, Faculty of Medicine, Zainoel Abidin General Hospital, Syiah Kuala University, Banda Aceh, Indonesia |  |\n|  |  |\n| Abstract \u003Cbr>Objective: Renal cell cancer (RCC) is the most typical form of kidney cancer in adults, which accounts for 80% to 85% of all primary renal neoplasms. RCC develops inside the renal cortex. This study aimed to systematically review the survival rate of patients treated with targeted therapy and/or RC. Surgery is the standard therapy for RCC, even though after surgery, 20%–40% of patients with localized RCC would experience distant metastases. Metastases or large RCC are not amenable to surgery. Unresectable RCC can be treated palliatively with angioembolization or neoadjuvant therapy. This study aims to review the survival rate comparisons ofangioembolization and neoadjuvant targeted therapy on unresectable renal cell carcinoma.\u003Cbr>Methods: Athorough search across databases such as PubMed, Cochrane Library, and ProQuest was conducted for articles published from 2018 to 2023. To uphold research integrity, duplicates, reviews, and incomplete articles were excluded, ensuring only pertinent and original research findings for subsequent analysis. Results: Database search yielded 247 articles, which were systematically eliminated, leaving 6 relevant articles. Analyzed articles showed the overall survival of patients treated with angioembolization and neoadjuvant agents.\u003Cbr>Conclusion: Unresectable RCC can be treated palliatively with angioembolization. Angioembolization may improve clinical effectiveness and lessen side effects by boosting local concentrations of drugs. Drug‑eluting bead transarterial chemoembolization is a novel embolization option that can embolize the arteries that feed the tumor and cutoff the blood supply to the tumor. Sunitinib, the most studied medicinal agent, was found to have higher effectiveness when combined with angioembolization.\u003Cbr>Keywords: Angioembolization, RCC, survival rate, targeted therapy |  |\n| Address for correspondence: Dr. Dahril Dahril, Department of Surgery, Urology Division, Faculty of Medicine, Universitas Syiah Kuala, Zainoel Abidin General Hospital, Banda Aceh, Indonesia.\u003Cbr>E‑[mail: dahril.fk@usk.ac.id](mail: dahril.fk@usk.ac.id)\u003Cbr>Received: 24.11. 2023, Accepted: 21.05. 2024, Published: 16.10.2024. |  |\n\nINTRODUCTION  \nRenal cell carcinoma (RCC) distinguishes itself as the predominant variant of kidney cancer in the adult  \n\n| Access this article online |  |\n| --- | --- |\n| Quick Response Code: | Website:\u003Cbr>[www.urologyannals.com](www.urologyannals.com) |\n| |  |\n|  | DOI:\u003Cbr>10.4103/ua. ua_114_23 |\n\ndemographic, comprising a noteworthy 80%–85% of all primary renal neoplasms and specifically manifesting its deleterious effects within the intricate confines of the  \nThis is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution‑NonCommercial‑ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.  \nFor reprints [contact:](contact: WKHLRPMedknow_reprints@wolterskluwer.com)[ WKHLRPMedknow_reprints@wolterskluwer.com](contact: WKHLRPMedknow_reprints@wolterskluwer.com)  \nHow to cite this article: Muhammad RY, Nurfajri DH, Dahril D, Ismy J. Survival rate comparisons of angioembolization and neoadjuvant targeted therapy on unresectable renal cell carcinoma patients: A systematic review. Urol Ann 2024;16:251-60 .  \n© 2024 Urology Annals | Published","cbCaidDp7ZqYu2IR","https://ap.wps.com/l/cbCaidDp7ZqYu2IR","pdf",869064,"English","# Abstract\n## Objective\n## Methods\n## Results\n## Conclusion\n# Introduction","[{\"question\":\"What condition does this systematic review focus on?\",\"answer\":\"Unresectable renal cell carcinoma (RCC) in patients requiring palliative treatment, where surgery is not suitable due to metastases or large tumor burden.\"},{\"question\":\"Which interventions are compared for survival outcomes?\",\"answer\":\"Angioembolization is compared with neoadjuvant targeted therapy agents in terms of overall survival.\"},{\"question\":\"How was the review conducted and what studies were included?\",\"answer\":\"Databases including PubMed, Cochrane Library, and ProQuest were searched for articles published from 2018 to 2023, with duplicates, reviews, and incomplete articles excluded, resulting in six relevant articles.\"}]","Survival rate comparisons of angioembolization and neoadjuvant targeted therapy on unresectable renal cell carcinoma patients - systematic review | PDF",1789999494,25]